Market-Moving News for May 1 st
$PALI
$SBUX
$TGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Restaurants
Consumer Discretionary
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/30/2026 | $110.00 → $116.00 | Overweight | Barclays | |
| 1/30/2026 | $100.00 → $103.00 | Overweight | Piper Sandler | |
| 1/23/2026 | Mkt Perform → Outperform | William Blair | ||
| 1/9/2026 | $7.00 | Buy | B. Riley Securities | |
| 12/29/2025 | $25.00 | Overweight | Piper Sandler | |
| 10/30/2025 | $84.00 → $83.00 | Neutral | Citigroup | |
| 10/28/2025 | $84.00 | Neutral | Mizuho | |
| 10/22/2025 | $115.00 → $95.00 | Overweight | Barclays |
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)
10-Q - STARBUCKS CORP (0000829224) (Filer)
8-K - STARBUCKS CORP (0000829224) (Filer)
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. Th
A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease. Christina Applegate, who has been living with MS for 5 years, will lead the new national disease-awareness initiative designed to elevate the voices of people living with MS, highlight the realities, and explore what comes next, on their own terms. The cornerstone of the campaign is www.NextInMS.com, a new platform developed to support p
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting, including updates from the ENABLE real world study evaluating patients with RMS on BRIUMVI. Our presentations reflect our continued focus on advancing the clinical understanding of
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - STARBUCKS CORP (0000829224) (Issuer)
Barclays reiterated coverage of Starbucks with a rating of Overweight and set a new price target of $116.00 from $110.00 previously
Piper Sandler reiterated coverage of Starbucks with a rating of Overweight and set a new price target of $103.00 from $100.00 previously
William Blair upgraded Starbucks from Mkt Perform to Outperform
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Sharon Skare, PhD(c) as Vice President, Global Head of Clinical Operations. Ms. Skare brings mor
Q1 Comparable Store Sales Accelerate to 4% Globally and in the U.S., Led by Transactions Company Delivers U.S. Comparable Transaction Growth for the First Time in Eight Quarters Q1 Consolidated Net Revenues Up 6% to $9.9 Billion Q1 GAAP EPS $0.26, Non-GAAP EPS $0.56 Company Introduces Fiscal Year 2026 Guidance Starbucks Corporation (NASDAQ:SBUX) today reported financial results for its 13-week fiscal first quarter ended December 28, 2025. GAAP results in fiscal 2026 include items that are excluded from non-GAAP results. Please refer to the reconciliation of GAAP measures to non-GAAP measures at the end of this release for more information. Q1 Fiscal Year 2026 Highlights Global compar
Starbucks Corporation (NASDAQ:SBUX) plans to release its first quarter fiscal year 2026 financial results at 7:45 a.m. Eastern Time on Wednesday, January 28, 2026, with a conference call to follow at 8:00 a.m. Eastern Time. The conference call will be webcast, including closed captioning, and can be accessed on the company's website at https://investor.starbucks.com/. A replay of the webcast will be available on the company's website until the end of day, Friday, March 13, 2025. About Starbucks Since 1971, Starbucks Coffee Company has been committed to ethically sourcing and roasting high-quality arabica coffee. Today, with more than 40,000 stores worldwide, the company is the premier r
Starbucks Corporation (NASDAQ:SBUX) today announced that its Board of Directors has approved a quarterly cash dividend of $0.62 per share of outstanding Common Stock. The dividend will be payable in cash on February 27, 2026, to shareholders of record on February 13, 2026. About Starbucks Since 1971, Starbucks Coffee Company has been committed to ethically sourcing and roasting high-quality arabica coffee. Today, with more than 40,000 stores worldwide, the company is the premier roaster and retailer of specialty coffee in the world. Through our unwavering commitment to excellence and our guiding principles, we bring the unique Starbucks Experience to life for every customer through every
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)